NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that it will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET. The event will feature presentations and live Q&A sessions with members of the Company’s executive leadership team and several exte ...

Core Viewpoint - AtaiBeckley NV has appointed Michael Faerm as chief financial officer, effective March 9, 2026, to enhance its financial strategy as it advances its mental health treatment pipeline [1]. Group 1: Appointment Details - Michael Faerm brings over 25 years of experience in life sciences, equity research, and investment banking [1]. - Faerm's previous roles include CFO at Viracta Therapeutics and interim CFO at Harpoon Therapeutics, which was acquired by Merck [2]. - He has also held positions at Innoviva, Forest Laboratories, and Regeneron Pharmaceuticals, focusing on business development and strategic finance [2]. Group 2: Financial Strategy and Leadership Transition - Faerm will oversee the company's financial strategy, capital markets activities, and overall financial operations [1]. - Current CFO Anne Johnson will transition to chief accounting officer, continuing to lead accounting and financial operations while supporting Faerm [3]. - The CEO of AtaiBeckley, Srinivas Rao, emphasized the importance of Faerm's strategic finance background as the company advances its lead candidate BPL-003 toward Phase 3 [4]. Group 3: Future Outlook - Faerm expressed enthusiasm about joining AtaiBeckley at a pivotal time, with BPL-003 advancing and a strong clinical-stage pipeline [5]. - He looks forward to collaborating with Johnson and the leadership team to support the company's late-stage development [6].

NEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026. Mr. Faerm is a seasoned financial executive with more than 25 years of experience across life sciences companies, equity research, and investm ...

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Jason Awe, Ph.D., Vice President of Investor Relations, will participate in fireside chats and host one-on-one meetings at the following investor conferenc ...

Group 1 - AtaiBeckley Inc. (NASDAQ:ATAI) is viewed positively by Wall Street, with analysts projecting a 12-month median price target indicating over 202% upside potential [1] - Patrick Trucchio from H.C. Wainwright has reiterated a Buy rating with a price target of $15, while Eddie Hickman from Guggenheim has initiated coverage with a Buy rating and a price target of $11 [1][2] - The company is recognized as a leader in next-generation psychiatry, particularly following its merger with Beckley Psytech, which grants full ownership of the promising asset BPL-003 [2] Group 2 - BPL-003 is designed to treat treatment-resistant depression and has demonstrated significant efficacy in Phase IIIb trials, showing sustained reductions in MADRS scores with a 63% responder rate and a 48% remission rate after a second dose [4] - Phase 3 trials for BPL-003 are scheduled for Q2 2026, following its designation as a Breakthrough Therapy by the FDA [4] - AtaiBeckley Inc. operates as a clinical-stage biopharmaceutical company focused on mental health treatments in the US, Germany, and Canada [4]

Core Insights - AtaiBeckley Inc. (NASDAQ:ATAI) is identified as a strong buy penny stock with multiple bullish ratings from various firms, indicating positive market sentiment towards the company [1][2]. Group 1: Ratings and Price Targets - H.C. Wainwright maintains a Buy rating on AtaiBeckley Inc. with a price target of $15 [1]. - Guggenheim initiated a Buy rating with a price target of $11, highlighting the company's leadership in next-generation psychiatry and the significance of its merger with Beckley Psytech [2]. - JonesTrading reaffirmed a Buy rating with a price target of $16, emphasizing the company's market opportunity and upcoming pivotal Phase II results expected in 2026 [2]. Group 2: Clinical Development and Market Position - The merger with Beckley Psytech allows AtaiBeckley complete ownership of BPL-003, which has shown compelling efficacy in treating treatment-resistant depression [2]. - The lead compounds BPL-003 and VLS-01 are considered well-suited for treatment-resistant depression due to their short duration of action, aligning with a clinic-based model similar to esketamine [3]. - AtaiBeckley is positioned for a data-rich 2026, with significant clinical developments anticipated across its pipeline [2].

AtaiBeckley Inc. (NASDAQ:ATAI) is one of Goldman Sachs’ top penny stock picks. On January 16 at the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), AtaiBeckley Inc. (NASDAQ:ATAI) delivered promising clinical data on BPL-003 for treatment-resistant depression. AtaiBeckley Inc. (ATAI) Gains Momentum With Promising BPL-003 Data and Strong Analyst Support Source:pixabay The results affirmed the development of transformative mental health therapies. The Phase 2b study for BPL-0 ...

Core Viewpoint - The article discusses the increasing interest in small and micro-cap stocks, particularly penny stocks, as investors seek opportunities amid concerns of a market correction, with Goldman Sachs highlighting its top 12 penny stock picks [1][4]. Market Performance - The S&P SmallCap 600 index has risen over 6% this year, while the iShares Micro Cap ETF is up about 8%. In contrast, the S&P 500 has only increased by 0.35% during the same period, indicating a shift in investor focus towards undervalued small-cap stocks [2]. - Small stocks have underperformed compared to large stocks in recent years, but there is an expectation of earnings growth that could lead to a rotation towards small-cap stocks [3]. Economic Outlook - Goldman Sachs maintains a positive macro outlook for small-cap stocks, predicting that the economic environment will support their performance through 2026. The expectation of interest rate cuts is seen as beneficial for penny and small-cap stocks [4][5]. - The firm believes that the markets are not fully accounting for the potential strength of the US economy in the coming year, which typically favors small-cap stocks during cyclical rallies [5]. Investment Strategy - Goldman Sachs' methodology for selecting its top penny stock picks involves analyzing equity holdings, focusing on companies trading under $5 per share, and considering their popularity among hedge funds [7]. - The strategy of imitating top hedge fund stock picks has historically outperformed the market, with a reported return of 427.7% since May 2014 [9]. Company Highlights - **Grupo Televisa, S.A.B. (NYSE:TV)**: Goldman Sachs holds an equity stake of $902,471, with a share price of $3.32. The company is expected to release its fourth-quarter results soon, with optimistic projections for 2026 due to favorable economic conditions in Mexico [10][11][12]. - **AtaiBeckley Inc. (NASDAQ:ATAI)**: Goldman Sachs has a stake of $2.38 million in AtaiBeckley, which is focused on developing treatments for mental health disorders. The company has shown promising clinical data for its drug BPL-003, which has received Breakthrough Therapy designation from the FDA [16][17][19][20].

Group 1 - AtaiBeckley Inc. (NASDAQ:ATAI) is recognized as a rapidly growing penny stock, with Guggenheim initiating coverage with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatry [1][3] - The recent merger with Beckley Psytech grants AtaiBeckley full ownership of BPL-003, which has demonstrated strong efficacy and durability in Phase IIIb trials for treatment-resistant depression, positioning it well for clinical adoption and commercial scaling [2] - JonesResearch also initiated coverage of AtaiBeckley with a Buy rating and a $16 price target, emphasizing the company's pipeline of psychedelic and empathogenic drugs as a unique opportunity in large neuropsychiatric markets, particularly focusing on BPL-003 and VLS-01 [3] Group 2 - AtaiBeckley Inc. is a clinical-stage biopharmaceutical company engaged in the research, development, and commercialization of mental health treatments in the US, Germany, and Canada [4]

Group 1 - AtaiBeckley Inc. (NASDAQ:ATAI) is recognized as a strong buy stock under $5, with a recent Buy rating from H.C. Wainwright and a price target of $15 [1] - Guggenheim initiated a Buy rating for AtaiBeckley on January 20, setting a price target of $11, citing the company's leadership in next-generation psychiatry and the promising asset BPL-003 for treatment-resistant depression [2] - JonesTrading maintained a Buy rating on AtaiBeckley on January 16, with a price target of $16, highlighting the company's market opportunity and an anticipated data-rich 2026 with pivotal Phase II results expected [2] Group 2 - AtaiBeckley Inc. is a clinical-stage biopharmaceutical company headquartered in Germany, focusing on mental health disorder treatments [3]